Clinical Trial Update: A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations [Phase 2]

View source ↗

Summary

Phase 2 study of CPI-613 (devimistat) for relapsed or refractory Burkitt lymphoma/leukemia and high-grade B-cell lymphoma with high-risk translocations is activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Leukemia
• Burkitt Lymphoma
• High-grade B-cell Lymphoma with Translocations

Drugs mentioned

• CPI-613 (devimistat)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma, Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING